Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Moon Haeng Hur, Yoon Jun Kim

Clin Mol Hepatol. 2025;31(1):e93-e95. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0943

View: 409 Download: 25

Letter to the Editor

Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li

Clin Mol Hepatol. 2025;31(1):e3-e4. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0832

View: 481 Download: 39

Editorial

Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon

Clin Mol Hepatol. 2024;30(4):659-662. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0516

View: 1186 Download: 81

Original Article

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0076

View: 4119 Download: 228 Web of Science: 8 Crossref: 9

Review

Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma

Edward Wolfgang Lee, Sarah Khan

Clin Mol Hepatol. 2017;23(4):265-272. Published online November 8, 2017

DOI: https://doi.org/10.3350/cmh.2017.0111

View: 11929 Download: 362 Web of Science: 38 Crossref: 36

Radioembolization for the treatment of hepatocellular carcinoma

Hyo-Cheol Kim

Clin Mol Hepatol. 2017;23(2):109-114. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0004

View: 13199 Download: 369 Web of Science: 50 Crossref: 44

Case Report

Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with ⁹⁰Y microspheres

Sun Young Yim, Jin Dong Kim, Jin Yong Jung, Chang Ha Kim, Yeon Seok Seo, Hyung Joon Yim, Soon Ho Um, Ho Sang Ryu, Yun Hwan Kim, Chong Suk Kim, Eun Shin

Clin Mol Hepatol. 2014;20(3):300-305. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.300

View: 8622 Download: 64 Web of Science: 9 Crossref: 11

1 |

Viewed By 6192	MAFLD: How is it different from NAFLD?
Viewed By 5279	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5005	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4169	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3943	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 155	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search